Related Experiment Video
Updated: Aug 11, 2025

11:16
Fabrication and Use of Dry Macroporous Alginate Scaffolds for Viral Transduction of T Cells
Published on: September 9, 2022
3.0K
Absorption rate governs cell transduction in dry macroporous scaffolds
Madelyn VanBlunk1,2, Vishal Srikanth3, Sharda S Pandit1,2
1Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, USA. ybrudno@ncsu.edu.
Biomaterials Science
|February 6, 2023
Summary
Dry macroporous alginate scaffolds enhance T cell transduction for cellular therapies. Faster liquid absorption into scaffolds, not pore size or stiffness, drives higher viral transduction efficiency.
Area of Science:
- Biomaterials Science
- Cellular Therapy
- Gene Therapy
Background:
- Novel biomaterials are crucial for advancing cellular therapies.
- Dry macroporous alginate scaffolds offer efficient retroviral transduction of T cells.
- This method, 'Drydux transduction,' rivals clinical spinoculation for CAR T cell production.
Purpose of the Study:
- To elucidate the mechanism of Drydux transduction.
- To investigate the influence of scaffold properties and viral parameters on transduction efficiency.
Main Methods:
- Systematic variation of scaffold pore size and stiffness.
- Testing different viral concentrations.
- Analyzing the impact of absorption speed on transduction.
- Utilizing a computational model for fluid flow analysis.
Main Results:
- Scaffold pore size (50-230 μm) and stiffness (25-620 kPa) did not significantly affect transduction efficiency.
- Increased viral concentration positively correlated with higher transduction rates.
- Faster absorption of cell-virus solution into scaffolds significantly improved transduction efficiency.
Conclusions:
- Drydux transduction efficiency is primarily regulated by the rate of liquid flow through the scaffold.
- Scaffold properties like pore size and stiffness are less critical than fluid dynamics.
- This understanding facilitates the optimization of biomaterial-based cellular therapies.

